At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 304 enrolled
Drug / intervention
Insulin Glarginedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label, Single-Arm, Phase 4 Study to Assess the Safety of Basaglar in Subjects With Type 2 Diabetes Mellitus in India
In Brief
A Phase 4 clinical trial evaluating Insulin Glargine for Type 2 Diabetes Mellitus. Completed, enrolled 304 participants across 11 sites.
Detailed Summary
The reason for this study is to see if insulin glargine is safe in participants with type 2 diabetes mellitus (T2DM) in India.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesIndia
Collaborators--
Timeline
Phase 4CompletedFinished
2020202120222023202420252026
First PostedNov 2019
Enrollment StartDec 2019
Primary CompletionJul 2021
TodayJul 2026
First PostedNov 6, 2019
Enrollment StartDec 16, 2019
Primary CompletionJul 30, 2021
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 6.7 years ago
Interventions
Insulin Glarginedrug
Administered SC